MedTrace Logo

Safety and Efficacy of DNK333 in Atopic Dermatitis Patients

NCT01033097 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-03-21

No results posted yet for this study

Summary

This study will assess the safety and efficacy of DNK333 in patients with atopic dermatitis suffering from pruritus, who require systemic treatment of the disease.

Conditions

  • Pruritus in Patients With Atopic Dermatitis

Interventions

DRUG

DNK333 5 mg

5 mg oral

DRUG

Placebo to 5 mg

5 mg placebo oral

DRUG

DNK333 25 mg

25 mg oral

DRUG

Placebo to 25 mg

25 mg placebo oral

DRUG

DNK333 100 mg

100 mg oral

DRUG

Placebo to 100 mg

100 mg placebo oral

DRUG

Betamethasone 4 mg

4 mg oral

DRUG

DNK333 1mg

1 mg oral

DRUG

Placebo to 1mg

1 mg placebo oral

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01033097 on ClinicalTrials.gov